MDGL NASDAQ
West Conshohocken, PA 19428
US
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Soergel David | S-Sale | 844 | $515.90 | 2026-05-18 |
| Dier Mardi | S-Sale | 646 | $431.94 | 2026-03-06 |
| Dier Mardi | S-Sale | 40 | $425.08 | 2026-03-06 |
| Dier Mardi | S-Sale | 420 | $426.86 | 2026-03-06 |
| Dier Mardi | S-Sale | 80 | $427.85 | 2026-03-06 |